#4 - Eli Lilly & Co. (NYSE:LLY)
When you’re looking for growth stocks for the next 10 years, it would be easy to put together a list that includes all AI stocks. But as the last couple of years have shown, there are other growth avenues for investors to pursue.
One of those comes from the GLP-1 revolution. What started out as a treatment for type-2 diabetes (T2D) has become an obesity treatment that is quickly becoming a mainstream weight-loss therapy. Eli Lilly & Co. (NYSE: LLY) is one of the leaders in this space with Mounjaro (T2D) and Zepbound (obesity).
The approval of these drugs resulted in 19% year-over-year revenue growth in 2023. That didn’t make its way to earnings, but that’s changing in 2024. Analysts expect 45.3% earnings growth in the next 12 months. And with the possibility of Medicare agreeing to cover GLP-1 drugs, those estimates may be too low.
And of the stocks listed here, Lilly is the only one that pays a consistent dividend (NVIDIA has recently started paying dividends). That’s a reason that LLY stock has generated a total return of over 1,600% for investors in the last 10 years.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More - Current Price
- $912.34
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 16 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $979.29 (7.3% Upside)
